NSAIDS and DMARDs Flashcards Preview

Dental Pharmacology > NSAIDS and DMARDs > Flashcards

Flashcards in NSAIDS and DMARDs Deck (48):
1

acetylsalisylic acid

aspirin

2

acetaminophen

tylenol

3

celecoxib: only COX2 inhibitor

celebrex

4

COX2 is inducible by ...

cytokines

5

NSAIDs do not inhibit ...

lipoxygenase

6

protection from cardiovascular disease is additional use of which NSAID

aspirin

7

which drug will close the ductus in neonates when it has remained patent

indomethacin

8

most common side effect of NSAIDs is ...

gastric or intestinal ulceration

9

all NSAIDs except ... tend to cause GI side effects

acetaminophen

10

aspirin covalently modifies both COX1 and COX2 ... ... cyclooxygenase activity

irreversibly inhibiting

11

aspirin ... COX enzymes

acetylates

12

side effects of which NSAID?: GI ulceration, tinnitus, reyes syndrome

aspirin

13

hepatic toxicity is a major side effect of which NSAID?

acetaminophen

14

therapeutic doses of ... do not produce gastric irritation or increase bleeding time

acetaminophen

15

antiinflammatory, analgesic, antipyretic; one of the more potent inhibitors of COX; useful for treatment of arthritis, gout; contraindicated in pregnancy

indomethacin

16

NSAID for postop pain and inflammation; administered intramuscularly or orally; inflammatory conditions in eye

ketorolac

17

potency is greater than indomethacin; non recommended for pregnant women; elevation of hepatic aminotransferase activities in plasma

diclofenac

18

approved as a transdermal NSAID

diclofenac

19

formulation of diclofenac and misoprotol (PGE1 analog) together that provides gastric protection

arthrotec

20

propionic acid derivatives

ibuprofen, naproxen, oxaprozin

21

half life of ibuprofen

2 hrs

22

half life of naproxen

14 hrs

23

half life of oxaprozin

40 hrs

24

equivalent of indomethacin or naproxen; principal advantage is its long half life of 50 hrs

piroxicam

25

more selective COX2 inhibitor although it will inhibit COX1

meloxicam

26

all NSAIDs ... hypotensive effect of antihypertensives

decrease

27

all NSAIDs ... natriuretic and diuretic effects of diuretic agents

decrease

28

all NSAIDs ... anticoagulant effect of oral anticoagulants

increase

29

treatment of all NSAIDs with potassium sparing diuretics, ACE inhibitors, B blockers has potential for

hyperkalemia

30

selective COX2 inhibitor; potential for CV problems

celecoxib

31

very commonly used DMARD; inhibitor of dihydrofolate reductase and interferes with de novo purine biosynthesis; has been used in treatment of various leukemias; treamtent of psoriasis

methotrexate

32

therapeutic effects of methotrexate are within ... weeks

4-6

33

.... supplements are recommended with methotrexate

folic acid

34

methotrexate can by co-administered with ...

glucocorticoids

35

2nd line DMARD; oral pyrimidine synthesis inhibitor; side effect of hepatic toxicity and liver failure

leflunomide

36

antimalarial agent and 2nd live agent used for mild rheumatoid athritis

hydroxychloroquine

37

treats RA, ulcertive colitis, Crohn's; prodrug; colonic bacteria release; 5-aminosalicylic acid-->therapeutic benefit

sulfasalazine

38

elevated ... levels found in synovial fluid of RA patients

TNF

39

major side effect of which class?: increased risk of infections

TNF inhibitors

40

decrease TNFa levels; false receptor; may be used in combo with methotrexate, NSAIDs or other agents (except antibodies directed against cytokines)

etanercept (enbrel)

41

chimeric IgG1 monoclonal antibody; high affinity binding to TNFa; inhibits interaction of TNFa with its receptors

infliximab (remicade)

42

human monoclonal TNFa antibody with human IgG; may be administered with other DMARDs (except biologics) or NSAIDs

adalimumab (humira)

43

TNF human monoclonal antibody; administered as monthly SQ injection

golimumab

44

TNF antibody conjugated to polyethylene glycol; monthly SQ injection

certolizumab

45

interleukin 1 receptor antagonist; one amino acid difference from IL 1; competitively inhibits IL 1

anakinra

46

T cell co stimulatory blocker; CTLA4 binds CD80 on antigen presenting cell and prevents interaction with CD20 on T cell

abatacept

47

depletes B cells; chimeric monoclonal antibody against CD20 on B cell surface

rituximab

48

monoclonal antibody against the IL 6 receptor

tocilzumab